Mustang Bio, Inc.
377 Plantation Street
Worcester
MA
01605
United States
Tel: 781-652-4500
Website: http://www.mustangbio.com/
Email: info@mustangbio.com
141 articles about Mustang Bio, Inc.
-
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
4/25/2022
Mustang Bio, Inc. today announced updated interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”).
-
Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations
4/21/2022
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”).
-
The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.
-
Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma
4/13/2022
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced its plan to initiate a Phase I clinical trial combining CAR T cells and oncolytic virus for the treatment of recurrent glioblastoma (rGBM), supported by interim data from two ongoing investigator-sponsored Phase 1 clinical trials evaluating two clinical candidates, MB-108 (C134 oncolytic virus) and MB‐101.
-
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
4/4/2022
Mustang Bio, Inc. today announced that members of Mustang’s management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022.
-
Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
3/23/2022
Mustang Bio, Inc. today announced financial results and recent corporate highlights for the full year ended December 31, 2021.
-
Mustang Bio to Participate in Three March 2022 Investor Conferences
3/10/2022
Mustang Bio, Inc. announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in March 2022.
-
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
3/9/2022
Mustang Bio, Inc. announced that an abstract reporting on Phase 1 trials being conducted at the UAB and City of Hope of Mustang Bio’s exclusively licensed oncolytic viral and CAR T-cell therapies for the treatment of patients with glioblastoma, has been selected as a late-breaking poster presentation at the AACR Annual Meeting 2022, taking place April 8 – 13, 2022, in New Orleans, Louisiana.
-
Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital
3/8/2022
Mustang Bio, Inc. today announced completion of a $75 million long-term debt facility with Runway Growth Capital LLC ("Runway"), a leading provider of growth loans to both venture and non-venture backed companies.
-
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium
2/15/2022
Mustang Bio, Inc. today announced that City of Hope Phase 1 clinical trial data on MB-105, a prostate stem cell antigen (“PSCA”) chimeric antigen receptor (“CAR”) T-cell therapy administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Shares of Mustang Bio have fallen more than 13% in premarket trading after announcing the FDA had placed a hold on the company’s Investigational New Drug application for its bubble boy gene therapy.
-
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
1/24/2022
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a hold, pending Chemistry, Manufacturing and Controls (“CMC”) clearance, on the Company’s Investigational New Drug (“IND”) application. Submitted in December 2021, the IND is to initiate a pivotal Phase 2 multicenter study to assess the safety, tolerability and efficacy of MB-207.
-
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
1/7/2022
The compelling clinical activity and favorable safety profile that MB-106 continues to demonstrate in the ongoing Phase 1/2 trial at Fred Hutch highlight its potential as an outpatient therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.
-
Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences
1/5/2022
Mustang Bio, Inc. announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2022.
-
Mustang Bio Added to the NASDAQ Biotechnology Index
12/16/2021
Mustang Bio, Inc. today announced that the company has been added to the NASDAQ Biotechnology Index® (NASDAQ: NBI).
-
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
12/13/2021
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”).
-
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
12/9/2021
Mustang Bio, Inc. today announced that it will host a key opinion leader (“KOL”) webinar on MB-106, the Company’s CD20-targeted, autologous CAR T cell therapy for the treatment of B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”), on Thursday, December 16, 2021, at 2:30 p.m. Eastern Time.
-
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
11/12/2021
Mustang Bio, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.